{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:17:24Z","timestamp":1790223444080,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy is a valuable treatment for many cancer patients, and there is considerable interest in understanding the mechanisms of immune evasion to guide appropriate management. Mycosis fungoides (MF) is a malignant disorder of skin-homing CD4+ T cells, and it exhibits a highly variable clinical course during which the tumor-specific immune response may be an important determinant. An unusual feature of MF is that tumor-infiltrating lymphocytes (TILs) must attempt to control a malignant cell from within their own lineage. We obtained skin biopsies and blood from 43 patients with CD4+ MF and undertook a detailed phenotypic and functional analysis of CD4+ and CD8+ T cells. Clonotypic TCRBV staining allowed delineation of malignant and reactive CD4+ subsets. CD4+ and CD8+ TILs displayed a comparable \u201cexhausted\u201d phenotype that was characterized by expression of PD-1 and TIGIT but retained cytotoxic activity and production of interferon-\u03b3 and interleukin-17 in early-stage disease. In contrast, tumor cells were much more heterogeneous and were divided into 3 discrete subsets based on differential expression of HLA-DR: \u201ccold\u201d (DR\u2212), \u201cexhausted\u201d (DR+ PD-1+), and \u201cevasive\u201d (DR++ PD-L1+) phenotypes. Disease progression was associated with increasing divergence of the tumor phenotype away from that of TILs and reduced functional activity within TILs. These observations reveal that the phenotype and function of TIL populations are constrained at all stages of disease, whereas the tumor evolves discrete phenotypic profiles of escape during clinical progression. The findings should help to direct appropriate immunotherapeutic interventions for individual patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018025114","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T16:55:23Z","timestamp":1550249723000},"page":"519-530","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-3725","authenticated-orcid":false,"given":"Duncan","family":"Murray","sequence":"first","affiliation":[{"name":"Instititute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Luke","family":"McMurray","sequence":"additional","affiliation":[{"name":"Instititute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"Eldershaw","sequence":"additional","affiliation":[{"name":"Instititute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden","family":"Pearce","sequence":"additional","affiliation":[{"name":"Instititute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Davies","sequence":"additional","affiliation":[{"name":"Instititute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8011-4408","authenticated-orcid":false,"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nuffield House, University Hospitals Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-1967","authenticated-orcid":false,"given":"Paul","family":"Moss","sequence":"additional","affiliation":[{"name":"Instititute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"issue":"suppl","key":"2020021108342629300_B1","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2020021108342629300_B2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021108342629300_B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2020021108342629300_B4","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"issue":"4","key":"2020021108342629300_B5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020021108342629300_B6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"2020021108342629300_B7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","article-title":"CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides","volume":"32","author":"Hoppe","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2020021108342629300_B8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am J Dermatopathol"},{"issue":"23","key":"2020021108342629300_B9","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020021108342629300_B10","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"2020021108342629300_B11","first-page":"181","volume":"128","author":"Khodadoust","year":"2016"},{"key":"2020021108342629300_B12","author":"R Core Team","year":"2017"},{"issue":"10","key":"2020021108342629300_B13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"key":"2020021108342629300_B14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"2020021108342629300_B15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"issue":"14","key":"2020021108342629300_B16","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020021108342629300_B17","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1182\/blood-2010-05-287664","article-title":"High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma","volume":"117","author":"Clark","year":"2011","journal-title":"Blood"},{"key":"2020021108342629300_B18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.anndiagpath.2017.02.003","article-title":"Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary\u2019s syndrome","volume":"28","author":"Nguyen","year":"2017","journal-title":"Ann Diagn Pathol"},{"issue":"3","key":"2020021108342629300_B19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjd.12934","article-title":"Expression of programmed death-1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma","volume":"171","author":"\u00c7etin\u00f6zman","year":"2014","journal-title":"Br J Dermatol"},{"issue":"7","key":"2020021108342629300_B20","doi-asserted-by":"crossref","first-page":"e1175799","DOI":"10.1080\/2162402X.2016.1175799","article-title":"Investigating potential exogenous tumor initiating and promoting factors for cutaneous T-cell lymphomas (CTCL), a rare skin malignancy","volume":"5","author":"Litvinov","year":"2016","journal-title":"OncoImmunology"},{"issue":"10","key":"2020021108342629300_B21","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archderm.1991.01680090067006","article-title":"The use of immunohistologic analysis in differentiating cutaneous T-cell lymphoma from psoriasis and dermatitis","volume":"127","author":"Verga","year":"1991","journal-title":"Arch Dermatol"},{"issue":"3","key":"2020021108342629300_B22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0625.1992.tb00005.x","article-title":"Differential localization of ICAM-1 and HLA-DR expression on epidermal basal surface in mycosis fungoides and lichenoid reaction","volume":"1","author":"Imayama","year":"1992","journal-title":"Exp Dermatol"},{"issue":"12","key":"2020021108342629300_B23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2020021108342629300_B24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in S\u00e9zary syndrome and mycosis fungoides","volume":"148","author":"Cetin\u00f6zman","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1","key":"2020021108342629300_B25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/PAS.0b013e318230df87","article-title":"Expression of programmed death-1 in primary cutaneous CD4-positive small\/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma","volume":"36","author":"Cetin\u00f6zman","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2020021108342629300_B26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2340\/00015555-2632","article-title":"High expression of Fas\/CD95 on CD4+ circulating T cells: an exclusion criterion in the diagnosis of mycosis fungoides?","volume":"97","author":"Du-Thanh","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2020021108342629300_B27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2133.2000.03656.x","article-title":"Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL","volume":"143","author":"Zoi-Toli","year":"2000","journal-title":"Br J Dermatol"},{"issue":"6","key":"2020021108342629300_B28","doi-asserted-by":"crossref","first-page":"1327.e1","DOI":"10.1016\/j.jaad.2012.05.035","article-title":"The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis","volume":"67","author":"Stutz","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2020021108342629300_B29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1523-1747.2002.01794.x","article-title":"Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin","volume":"118","author":"Dereure","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2020021108342629300_B30","first-page":"261","article-title":"Intraepidermal but not dermal T lymphocytes are positive for a cell-cycle-associated antigen (Ki-67) in mycosis fungoides","volume":"136","author":"Nickoloff","year":"1990","journal-title":"Am J Pathol"},{"issue":"1","key":"2020021108342629300_B31","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"2020021108342629300_B32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cellsig.2017.05.008","article-title":"The HLA-DR mediated signalling increases the migration and invasion of melanoma cells, the expression and lipid raft recruitment of adhesion receptors, PD-L1 and signal transduction proteins","volume":"36","author":"Costantini","year":"2017","journal-title":"Cell Signal"},{"key":"2020021108342629300_B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.12.007","article-title":"A cellular and molecular view of T helper 17 cell plasticity in autoimmunity","volume":"87","author":"Stadhouders","year":"2018","journal-title":"J Autoimmun"},{"issue":"3","key":"2020021108342629300_B34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1078-0432.CCR-07-0610","article-title":"Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"14","author":"Chong","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020021108342629300_B35","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/jid.2011.27","article-title":"Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3\/Stat3 signaling pathway","volume":"131","author":"Krejsgaard","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2020021108342629300_B36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/1523-1747.ep12292129","article-title":"Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma","volume":"108","author":"Asadullah","year":"1997","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2020021108342629300_B37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00403-006-0705-x","article-title":"Abnormal expression of interleukin-23 in mycosis fungoides\/S\u00e9zary syndrome lesions","volume":"298","author":"Doherty","year":"2006","journal-title":"Arch Dermatol Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/519\/1631210\/advances025114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/519\/1631210\/advances025114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:05:11Z","timestamp":1581411911000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/4\/519\/246764\/Progression-of-mycosis-fungoides-occurs-through"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018025114","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}